Brexit; Deal or No Deal the damage is done

Do we have a deal? Does it actually matter to the general public any more? The PM is committed to delivering what we the people asked for, but honestly does anyone care any more, do you?

From my perspective so many companies I work with have changed their strategy already its too late to turn back, we as a nation have suffered the damage already. I don't know how many licensed sites have decided to cease trading, or to move their manufacturing capabilities out of the UK. Its hard to say the changes were purely because of Brexit or if the move was already under weigh. Business has to go on so if you see a risk as significant as Brexit then you have to (in my opinion) review it against your overall business strategy, assess the risk, document your decision and take action. When circumstances change its time to review, these could be internal or external. Unfortunately many companies fail to develop a company or corporate strategy, those who do often only commit to the management rhetoric of corporate strategy. Still others put the strategy in place but fail to embed it in their culture and subsequently make decisions without reference to their strategic "focus".

For the politicians caution seems to be the name of the game now, its a real shame there wasn't more effort put into the referendum. The whole tour of the country by the PM should be a reminder of what happened then but unfortunately complacency then put us in the situation we are in now.

With all change comes opportunity.

If you are ambitious will you get to where you want to be with out change? Of course not, the same is true in business, those who do the same thing or even the same sequence of activities and expect a different result are usually disappointed. Consider the opportunities, maybe a competitor relocated to France or Germany, will they be able to serve your local customers the way they used to and with the same service which you can offer? Probably not, so there's an opportunity for you to gain market share. Similarly the open market shared within Europe may nolonger be as open to free trade, so your European competitors may feel they are at a disadvantage, note feel there may be nothing but personal opinion to support this feeling. That doesn't make it wrong though, so as European's are carrying out their own risk assessments their decisions may be similar but with a positive impact as they reduce their spend in the UK. While some Pharmaceutical consultants have already moving to mainland Europe, others are opening a new office just in case. Manufacturers are moving their registered office and taking their EU licences with them, so when you apply for your new bio-similar for the UK market only there will nolonger be any reason for the MHRA to say no to your new licence to supply with a competitive advantage since you will not need to accommodate a multilingual pack.